CD274 and gastric cancer: The CheckMate-649 study demonstrated that patients with positive PD-L1 expression may benefit from the combination of nivolumab and chemotherapy, establishing the foundation for using immunotherapy combined with chemotherapy as a first-line treatment for gastric cancer.24